The role of polysaccharide peptides of miselia Ganoderma lucidum extracts on IL-1, IL-6, HSCRP and no in dislipidemic patients with or without hypertension in STEMI and NSTEMI patients

Individuals with metabolic syndrome have an increased risk of cardiovascular disease such as coronary heart disease. With the occurrence of a metabolic syndrome consisting of dyslipidemia, hypertension and type 2 diabetes mellitus, inflammation of the endothelial wall activates proinflammatory molecules such as IL-1, IL-6 and hsCRP and decreases the production of nitric oxide which causes atherosclerosis. The purpose of this study was to determine and prove the effect of giving PsP (Polysaccharide Peptide) from mycelia extract as an anti-inflammatory in patients with ST-myocardial infarction (STEMI) and non-ST elevation of myocardial infarction (NSTEMI). This study was true experimental using a randomized controvert perspective method with pre-test and post-test design, to determine the effect of giving Peptide Polysaccharide from mycelia Extract for secondary prevention and reducing morbidity in STEMI patients. A sample of 46 participants was obtained. The results of the analysis with the paired t-test showed that Polysaccharide Peptides from the extract of Ganoderma Lucidum mycelia could act as anti- inflammatory so as to reduce the risk of myocardial infarction by decreasing IL-1, IL-6 and CRP hs (p- value 0.018, 0.300 and 0.026) and increase NO (p-value 0.014) in patients with comorbid dyslipidemia and decreased levels of IL-1, IL6 and hsCRP (p-value 0.094, 0.928, and 0.014) and increase in NO (p- value 0.095) in patients with dyslipidemia and hypertension.